ABSTRACT
Purpose Solid organ transplant (SOT) recipients can develop skeletal diseases caused by underlying conditions and the use of immunosuppressants. As a result, SOT recipients are at risk for decreased bone mineral density (BMD) and increased fracture incidences. We propose a network meta-analysis (NMA) that incorporates all available RCT data to provide the most comprehensive ranking of antiresorptive interventions according to their ability to decrease fracture incidences and increase BMD in SOT recipients.
Methods We will search MEDLINE, EMBASE, Web of Science, CINAHL, CENTRAL and Chinese literature sources for RCTs, and we will include adult SOT recipients who took antiresorptive therapies starting at the time of transplant with relevant outcomes. We will perform title and full-text screening as well as data extraction in duplicate. We will report changes in BMD as weighted or standardized mean differences, and fracture incidences as risk ratios. We will use SUCRA scores to provide rankings of interventions, and we will examine the quality of evidence using risk of bias and CINeMA.
Results The results of this systematic review and network meta-analysis will be published in a peer-reviewed journal.
Conclusions To our knowledge, this systematic review and network meta-analysis will be the most comprehensive quantitative analysis regarding the management of bone loss and fractures in SOT recipients. Our analysis should be able to provide physicians and patients with an up-to-date recommendation for pharmacotherapies in reducing incidences of bone loss and fractures associated with SOT.
CONFLICT OF INTEREST Jiawen Deng, and Wenteng Hou declare that they have no conflict of interest.
MINI ABSTRACT We propose a network meta-analysis investigating the use of antiresorptive interventions to prevent bone loss and fractures in solid organ transplant (SOT) recipients. We aim to provide a comprehensive ranking of antiresorptive therapies in terms of their ability to increase bone mineral density and decrease fracture incidence in SOT recipients.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
CRD42019138807
Funding Statement
No external funding was received.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email Jiawen Deng: dengj35{at}mcmaster.ca
Wenteng Hou: houw3{at}mcmaster.ca
Data Availability
All available data are presented in the manuscript and supplementary materials.
